Qu – which, according to Parsa, is the fruit of a collaboration between a global team of experienced AI scientists, ...

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after ...

Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

How will AI continue to transform drug development? What’s next for cell and gene therapy? Who will take the crown in the ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

Today, we live in an age of artificial intelligence (AI); more specifically, the age of generative AI (GenAI). In a recent report, 65% of respondents stated that their organisations are regularly ...

In today’s fast-paced world, threats can evolve quickly and without warning. As the pharmaceutical industry has operations and supply chains spanning the globe, companies are vulnerable to ...

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage. Ben Hargreaves outlines how oncology is a priority for research, and how ...